

# Winson Y Cheung

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4157560/publications.pdf>

Version: 2024-02-01

169  
papers

2,258  
citations

279701

23  
h-index

345118

36  
g-index

171  
all docs

171  
docs citations

171  
times ranked

3963  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality and Resource Use Among Individuals With Chronic Kidney Disease or Cancer in Alberta, Canada, 2004-2015. <i>JAMA Network Open</i> , 2022, 5, e2144713.	2.8	8
2	Changing Rates of Goals of Care Designations in Patients With Advanced Pancreatic Cancer During a Multifactorial Advanced Care Planning Initiative: A Real-World Evidence Study. <i>JCO Oncology Practice</i> , 2022, 18, e869-e876.	1.4	1
3	Developing a Prediction Model for Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Model Building Approaches. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100055.	1.0	3
4	Top 10 research priorities for early-stage colorectal cancer: a Canadian patient-oriented priority-setting partnership. <i>CMAJ Open</i> , 2022, 10, E278-E287.	1.1	4
5	A Population-Based Study to Evaluate the Associations of Nodal Stage, Lymph Node Ratio and Log Odds of Positive Lymph Nodes with Survival in Patients with Small Bowel Adenocarcinoma. <i>Current Oncology</i> , 2022, 29, 1298-1308.	0.9	4
6	A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires. <i>Journal of Clinical Medicine</i> , 2022, 11, 1271.	1.0	1
7	Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis. <i>BMC Cancer</i> , 2022, 22, 255.	1.1	11
8	Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group. <i>Current Oncology</i> , 2022, 29, 2046-2063.	0.9	2
9	Incident Cardiovascular Disease Among Adults With Cancer. <i>JACC: CardioOncology</i> , 2022, 4, 85-94.	1.7	55
10	Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort. <i>Current Oncology</i> , 2022, 29, 1967-1982.	0.9	1
11	Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada. <i>Oncology and Therapy</i> , 2022, 10, 195-210.	1.0	5
12	Average lifespan shortened due to Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia in Japan, 1990-2015. <i>Leukemia and Lymphoma</i> , 2022, 63, 2084-2093.	0.6	2
13	Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). <i>Trials</i> , 2022, 23, 420.	0.7	6
14	Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada. <i>Journal of Clinical Oncology</i> , 2022, 40, e17624-e17624.	0.8	0
15	Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, e75-e81.	1.0	6
16	Factors associated with the initiation of chemotherapy within 90 days of death in metastatic colorectal cancer patients: a population-based study. <i>Supportive Care in Cancer</i> , 2021, 29, 1535-1542.	1.0	2
17	Symptom burden in patients with common cancers near end-of-life and its associations with clinical characteristics: a real-world study. <i>Supportive Care in Cancer</i> , 2021, 29, 3299-3309.	1.0	12
18	Dosimetric Parameters Predicting Late Small Bowel Toxicity in Patients With Rectal Cancer Receiving Neoadjuvant Chemoradiation. <i>Practical Radiation Oncology</i> , 2021, 11, e70-e79.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Patient-Reported Symptom Burden Near the End of Life in Patients With Gynaecologic Cancers. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 26-33.	0.3	0
20	Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2034201.	2.8	4
21	Average Lifespan Shortened due to Stroke in Canada. <i>Stroke</i> , 2021, 52, 573-581.	1.0	4
22	Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer. <i>JAMA Network Open</i> , 2021, 4, e213587.	2.8	9
23	Oncology Clinicians'™ Challenges to Providing Palliative Cancer Care"™ A Theoretical Domains Framework, Pan-Cancer System Survey. <i>Current Oncology</i> , 2021, 28, 1483-1494.	0.9	2
24	More Is Not Better When It Comes to Treating Rectal Cancer With Multimodal Chemoradiation Beyond the Standard Radiation Dose of 5040 cGy. <i>Diseases of the Colon and Rectum</i> , 2021, Publish Ahead of Print, .	0.7	3
25	Average lifespan shortened due to breast cancer in Australia, 1990"™2015. <i>Breast Cancer</i> , 2021, 28, 1389-1391.	1.3	4
26	Effects of Exercise on Cancer Treatment Efficacy: A Systematic Review of Preclinical and Clinical Studies. <i>Cancer Research</i> , 2021, 81, 4889-4895.	0.4	34
27	Associations of Socioeconomic Status and Rurality With New-Onset Cardiovascular Disease in Cancer Survivors: A Population-Based Analysis. <i>JCO Oncology Practice</i> , 2021, 17, e1189-e1201.	1.4	3
28	Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 519-525.	0.6	0
29	Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada. <i>Current Oncology</i> , 2021, 28, 3091-3103.	0.9	14
30	Impact of new cancer therapies on outpatient treatment delivery for colorectal cancer: A population"™based study. <i>International Journal of Health Planning and Management</i> , 2021, , .	0.7	0
31	Real-World Outcomes of Oxaliplatin-Based Chemotherapy on R0 Resected Colonic Liver Metastasis. <i>Clinical Colorectal Cancer</i> , 2021, 20, e201-e209.	1.0	0
32	Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 787-799.	0.9	12
33	Impact of cancer diagnosis on causes and outcomes of 5.9 million US patients with cardiovascular admissions. <i>International Journal of Cardiology</i> , 2021, 341, 76-83.	0.8	15
34	Higher-risk breast cancer in women aged 80 and older: Exploring the effect of treatment on survival. <i>Breast</i> , 2021, 59, 203-210.	0.9	6
35	Patient and family financial burden associated with cancer treatment in Canada: a national study. <i>Supportive Care in Cancer</i> , 2021, 29, 3377-3386.	1.0	43
36	Living with paradox: A qualitative study of colorectal cancer patients"™ experiences in managing their health after cancer treatment. <i>European Journal of Cancer Care</i> , 2021, 30, e13416.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis. <i>Current Oncology</i> , 2021, 28, 3978-3986.	0.9	7
38	Associations Between the Density of Oil and Gas Infrastructure and the Incidence, Stage and Outcomes of Solid Tumours: A Population-Based Geographic Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 757875.	1.3	0
39	Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database. <i>Current Oncology</i> , 2021, 28, 4213-4222.	0.9	10
40	A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100249.	0.6	14
41	Premature deaths due to head and neck cancers in canada: A nationwide analysis from 1980 to 2010. <i>Laryngoscope</i> , 2020, 130, 911-917.	1.1	8
42	Accrual of older adults to cancer clinical trials led by the Canadian cancer trials group – Is trial design a barrier?. <i>Journal of Geriatric Oncology</i> , 2020, 11, 455-462.	0.5	10
43	Physical Activity and Mortality in Cancer Survivors: A Systematic Review and Meta-Analysis. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz080.	1.4	205
44	Medical Cannabis Authorization in Patients With Cancer in the Prelegalization Era: A Population-Based Study. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 1223-1231.	0.6	3
45	Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy. <i>Oncologist</i> , 2020, 25, 212-217.	1.9	7
46	Patient perspectives on primary care and oncology care coordination in the context of multiple chronic conditions: A systematic review. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1003-1016.	1.5	23
47	Real-World Adherence to Guideline-Recommended Treatment for Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 236-242.	0.6	14
48	Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer. <i>BMC Cancer</i> , 2020, 20, 1004.	1.1	16
49	Characterizing Urban-Rural Differences in Colon Cancer Outcomes. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 531-535.	0.6	10
50	Eligibility of real-world patients with metastatic breast cancer for clinical trials. <i>Breast</i> , 2020, 54, 171-178.	0.9	10
51	Development of a Model for Predicting Early Discontinuation of Adjuvant Chemotherapy in Stage III Colon Cancer. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 972-984.	1.0	4
52	Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State. <i>JCO Oncology Practice</i> , 2020, 16, e1543-e1552.	1.4	6
53	Premature mortality due to stomach cancer in Japan: a nationwide analysis from 1980 to 2015. <i>Annals of Epidemiology</i> , 2020, 47, 19-24.	0.9	12
54	Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials. <i>Clinical Colorectal Cancer</i> , 2020, 19, e226-e234.	1.0	13

#	ARTICLE	IF	CITATIONS
55	Obesity and Its Impact on Outcomes in Patients With Stage III Colon Cancer Receiving Adjuvant Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2020, 19, 209-218.	1.0	6
56	Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. <i>Oral Oncology</i> , 2020, 102, 104526.	0.8	37
57	Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta-analysis. <i>Cancer Medicine</i> , 2020, 9, 1613-1627.	1.3	11
58	Patient-reported symptom burden and supportive care needs at cancer diagnosis: a retrospective cohort study. <i>Supportive Care in Cancer</i> , 2020, 28, 5889-5899.	1.0	22
59	Associations Between Physician Prescribing Behavior and Persistent Postoperative Opioid Use Among Cancer Patients Undergoing Curative-intent Surgery. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	2.1	4
60	Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma. <i>Oncologist</i> , 2020, 25, 438-446.	1.9	56
61	Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 604-618.	0.8	9
62	A real-world observational study of somatostatin analogue use and costs in Canada.. <i>Journal of Clinical Oncology</i> , 2020, 38, 608-608.	0.8	3
63	Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada. <i>Blood</i> , 2020, 136, 21-21.	0.6	0
64	Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
65	Causes of mortality in older patients with stage 3 colon cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 138-142.	0.5	16
66	The use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 132-137.	0.5	15
67	Introduction of a novel measure of premature mortality caused by chronic conditions: real-world examples from prostate and testis cancers in Canada, 1980-2015. <i>Annals of Epidemiology</i> , 2019, 37, 81-83.	0.9	8
68	Self-management interventions for cancer survivors: A systematic review and evaluation of intervention content and theories. <i>Psycho-Oncology</i> , 2019, 28, 2119-2140.	1.0	84
69	Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes. <i>Breast Cancer: Basic and Clinical Research</i> , 2019, 13, 117822341987942.	0.6	7
70	Population-based assessment of the performance of sigmoidoscopy in the detection of colorectal cancer: implications for future screening recommendations. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 354-356.	0.6	3
71	Population-based assessment of the national comprehensive cancer network recommendations for baseline imaging of hepatocellular carcinoma. <i>Medical Oncology</i> , 2019, 36, 26.	1.2	0
72	Developing case-finding algorithms for second events of oropharyngeal cancer using administrative data: A population-based validation study. <i>Head and Neck</i> , 2019, 41, 2291-2298.	0.9	3

#	ARTICLE	IF	CITATIONS
73	Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Nonâ€“Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 75-81.	0.6	10
74	Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study. <i>Lung Cancer</i> , 2019, 134, 141-146.	0.9	8
75	Chronic Postoperative Opioid Use: A Systematic Review. <i>World Journal of Surgery</i> , 2019, 43, 2164-2174.	0.8	24
76	Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer. <i>JAMA Network Open</i> , 2019, 2, e194154.	2.8	23
77	Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data. <i>BMC Cancer</i> , 2019, 19, 210.	1.1	29
78	Population-based assessment of the National Comprehensive Cancer Network recommendations for baseline imaging of rectal cancer. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1167-1172.	0.6	1
79	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 196-201.	0.6	12
80	Impact of Baseline Cardiovascular Comorbidity on Outcomes in Women With Breast Cancer: A Real-world, Population-based Study. <i>Clinical Breast Cancer</i> , 2019, 19, e297-e305.	1.1	8
81	A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 62-68.	0.6	51
82	Role of surveillance imaging and endoscopy in colorectal cancer follow-up: Quality over quantity?. <i>World Journal of Gastroenterology</i> , 2019, 25, 59-68.	1.4	21
83	Premature Mortality Due to Malignancies of the Central Nervous System in Canada, 1980â€“2010. <i>Neuroepidemiology</i> , 2018, 50, 195-200.	1.1	11
84	Impact of smoking history on the outcomes of women with early-stage breast cancer: a secondary analysis of a randomized study. <i>Medical Oncology</i> , 2018, 35, 68.	1.2	11
85	Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 156-163.	1.0	24
86	External validation of the prostatascore model in patients with metastatic hormoneâ€“sensitive prostate cancer recruited to the CHARTED study. <i>BJU International</i> , 2018, 122, 394-400.	1.3	1
87	Advanced imaging and hospice use in end-of-life cancer care. <i>Supportive Care in Cancer</i> , 2018, 26, 3619-3625.	1.0	4
88	Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 643-648.	0.6	7
89	Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 429-436.	0.6	4
90	Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e21-e28.	1.0	7

#	ARTICLE	IF	CITATIONS
91	Urban and rural differences in outcomes of head and neck cancer. <i>Laryngoscope</i> , 2018, 128, 852-858.	1.1	17
92	Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 55-55.	1.5	1
93	Effectiveness and components of self-management interventions in adult cancer survivors: a protocol for a systematic review and planned meta-analysis. <i>Systematic Reviews</i> , 2018, 7, 238.	2.5	9
94	Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-11.	0.8	33
95	A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer. <i>Cancer Medicine</i> , 2018, 7, 6385-6392.	1.3	13
96	The effect of comorbidities on outcomes in colorectal cancer survivors: a population-based cohort study. <i>Journal of Cancer Survivorship</i> , 2018, 12, 733-743.	1.5	27
97	The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-4.	0.8	7
98	Thyroid nodule ultrasound reports in routine clinical practice provide insufficient information to estimate risk of malignancy. <i>Endocrine</i> , 2018, 61, 303-307.	1.1	19
99	“Driving” Rates Down: A Population-Based Study of Opening New Radiation Therapy Centers on the Use of Mastectomy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2994-3003.	0.7	5
100	Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting. <i>Medical Oncology</i> , 2018, 35, 110.	1.2	6
101	Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy. <i>Medical Oncology</i> , 2018, 35, 114.	1.2	3
102	A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes. <i>Medical Oncology</i> , 2018, 35, 116.	1.2	13
103	A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-10.	0.8	11
104	Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. <i>Medical Oncology</i> , 2018, 35, 123.	1.2	10
105	Sex Disparities in Outcomes of Early Stage Colorectal Cancer: A Population-Based Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e711-e717.	1.0	12
106	Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 466-472.	0.9	7
107	Integrating Systemic Therapies into the Multimodality Treatment of Resectable Colorectal Liver Metastases. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-4.	0.7	8
108	Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer. <i>Medical Oncology</i> , 2018, 35, 117.	1.2	40

#	ARTICLE	IF	CITATIONS
109	Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients. <i>Medical Oncology</i> , 2018, 35, 125.	1.2	3
110	Long-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2018, 7, 4801-4813.	1.3	35
111	Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 65-72.	1.0	14
112	Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 552-554.	0.6	19
113	The utility of abbreviated patient-reported outcomes for predicting survival in early stage colorectal cancer. <i>Cancer</i> , 2017, 123, 1839-1847.	2.0	17
114	Young adult cancer survivors' follow-up care expectations of oncologists and primary care physicians. <i>Journal of Cancer Survivorship</i> , 2017, 11, 295-301.	1.5	10
115	Asian and non-Asian disparities in outcomes of non-nasopharyngeal head and neck cancer. <i>Laryngoscope</i> , 2017, 127, 2528-2533.	1.1	4
116	Subsequent thoracic cancers among patients diagnosed with lung cancer: a SEER database analysis. <i>Current Medical Research and Opinion</i> , 2017, 33, 2009-2017.	0.9	14
117	Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation. <i>Cmaj</i> , 2017, 189, E1030-E1040.	0.9	40
118	Population-Based Patterns and Factors Associated With Underuse of Palliative Systemic Therapy in Elderly Patients With Metastatic Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 147-153.	1.0	18
119	A Comparison of Survival by Site of Metastatic Resection in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e23-e28.	1.0	4
120	Impact of Travel Distance and Urban-Rural Status on the Multidisciplinary Management of Rectal Cancer. <i>Journal of Rural Health</i> , 2017, 33, 393-401.	1.6	33
121	A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy. <i>Thyroid Research</i> , 2017, 10, 6.	0.7	11
122	Effect of advanced age, elevated bilirubin, and disease extent on outcomes of unresectable pancreatic cancer (UPC) patients receiving first-line chemotherapy: A population-based study. <i>Journal of Clinical Oncology</i> , 2017, 35, 325-325.	0.8	1
123	The effect of sorafenib (S) starting dose and dose intensity on survival in patients with advanced hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2017, 35, 400-400.	0.8	2
124	Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 680-680.	0.8	3
125	Evolving treatment landscape for early and advanced pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 281.	0.8	26
126	Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 710-710.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.. Journal of Clinical Oncology, 2017, 35, 758-758.	0.8	0
128	A population-based analysis of urban-rural disparities in advanced pancreatic cancer (APC) management and outcomes.. Journal of Clinical Oncology, 2017, 35, 254-254.	0.8	0
129	Oncopre: A new chemotherapy benefit prediction algorithm to assist treatment decision making.. Journal of Clinical Oncology, 2017, 35, 705-705.	0.8	0
130	Cost-effectiveness of surveillance after curative resection (CR) of metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2017, 35, 526-526.	0.8	0
131	ECOG performance status as a predictor of adjuvant chemotherapy (AC) toxicities in stage III colorectal cancer (CRC) patients.. Journal of Clinical Oncology, 2017, 35, 789-789.	0.8	1
132	Primary care vs. oncology-driven surveillance following adjuvant chemotherapy in resected pancreas cancer.. Journal of Clinical Oncology, 2017, 35, 421-421.	0.8	4
133	Sequential treatment in patients with metastatic pancreatic neuroendocrine tumors after progression on first-line therapy.. Journal of Clinical Oncology, 2017, 35, 426-426.	0.8	0
134	Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 468-468.	0.8	1
135	ONCOPRE: A new chemotherapy benefit prediction model to assist treatment decision making.. Journal of Clinical Oncology, 2017, 35, 126-126.	0.8	0
136	Trends in the content and format of main and optional consent forms in oncology clinical trials.. Journal of Clinical Oncology, 2017, 35, 153-153.	0.8	0
137	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. Healthcare Policy, 2017, 12, 95-108.	0.3	19
138	A qualitative focus group study to identify the needs of survivors of stage II and III colorectal cancer. Psycho-Oncology, 2016, 25, 1470-1476.	1.0	34
139	Correlation between County-Level Surgeon Density and Mortality from Colorectal Cancer. Journal of Gastrointestinal Cancer, 2016, 47, 389-395.	0.6	10
140	Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 2016, 15, 179-185.	1.0	38
141	Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy. Clinical Colorectal Cancer, 2016, 15, 352-359.e1.	1.0	12
142	Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data. Cancer Medicine, 2016, 5, 1776-1782.	1.3	6
143	Leveraging the power of pooled data for cancer outcomes research. Chinese Journal of Cancer, 2016, 35, 74.	4.9	1
144	Optimizing adjuvant therapy and survivorship care of stage III colon cancer. Future Oncology, 2016, 12, 2021-2035.	1.1	12

#	ARTICLE	IF	CITATIONS
145	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 1182-1189.	0.8	32
146	Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes. <i>Clinical Colorectal Cancer</i> , 2016, 15, 16-23.	1.0	20
147	Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 158-163.	1.0	4
148	Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients. <i>Supportive Care in Cancer</i> , 2016, 24, 1199-1208.	1.0	11
149	Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 799-805.	1.0	9
150	Colorectal cancer screening: Opportunities to improve uptake, outcomes, and disparities. <i>World Journal of Gastrointestinal Endoscopy</i> , 2016, 8, 733.	0.4	14
151	Time to Adjuvant Chemotherapy and Survival Outcomes Among Patients With Stage 2 to 3 Rectal Cancer Treated With Preoperative Chemoradiation. <i>Clinical Colorectal Cancer</i> , 2015, 14, 41-45.	1.0	13
152	Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 262-268.e1.	1.0	17
153	Comparative adherence to oral hormonal agents in older women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 419-427.	1.1	14
154	Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 25-30.	1.0	14
155	Effect of M1a and M1b Category in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2014, 19, 720-726.	1.9	13
156	Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 394-400.	0.1	0
157	Acute gout episodes during treatment with capecitabine: a case report. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 59-60.	0.8	2
158	Appropriateness of cardiovascular care in elderly adult cancer survivors. <i>Medical Oncology</i> , 2013, 30, 561.	1.2	10
159	Physician preferences and attitudes regarding different models of cancer survivorship care: a comparison of primary care providers and oncologists. <i>Journal of Cancer Survivorship</i> , 2013, 7, 343-354.	1.5	105
160	Enrollment and Events of Hospice Patients With Heart Failure vs. Cancer. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 552-560.	0.6	41
161	The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database. <i>Clinical Colorectal Cancer</i> , 2013, 12, 179-187.	1.0	27
162	Difficult to Swallow: Issues Affecting Optimal Adherence to Oral Anticancer Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 265-270.	1.8	4

#	ARTICLE	IF	CITATIONS
163	Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. International Journal of Cancer, 2012, 131, 2478-2486.	2.3	27
164	Adherence to guidelines for adjuvant chemotherapy (AC) use in stage II colon cancer (CC).. Journal of Clinical Oncology, 2012, 30, 169-169.	0.8	0
165	Analysis of Wait Times and Costs During the Peri-Diagnostic Period for Non-Small Cell Lung Cancer. Lung Cancer, 2011, 72, 125-131.	0.9	18
166	Pharmacologic Management of Cancer-Related Pain, Dyspnea, and Nausea. Seminars in Oncology, 2011, 38, 450-459.	0.8	15
167	Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk. Carcinogenesis, 2009, 30, 1363-1367.	1.3	14
168	Validated algorithms for identifying timing of second event of oropharyngeal squamous cell carcinoma using real-world data. Head and Neck, 0, , .	0.9	0
169	Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma. Canadian Liver Journal, 0, , .	0.3	0